These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

176 related articles for article (PubMed ID: 32999833)

  • 1. Mucosal Vaccination for Influenza Protection Enhanced by Catalytic Immune-Adjuvant.
    Qin T; Ma S; Miao X; Tang Y; Huangfu D; Wang J; Jiang J; Xu N; Yin Y; Chen S; Liu X; Yin Y; Peng D; Gao L
    Adv Sci (Weinh); 2020 Sep; 7(18):2000771. PubMed ID: 32999833
    [TBL] [Abstract][Full Text] [Related]  

  • 2. CpG Oligodeoxynucleotides Facilitate Delivery of Whole Inactivated H9N2 Influenza Virus via Transepithelial Dendrites of Dendritic Cells in Nasal Mucosa.
    Qin T; Yin Y; Yu Q; Huang L; Wang X; Lin J; Yang Q
    J Virol; 2015 Jun; 89(11):5904-18. PubMed ID: 25810544
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Whole inactivated avian Influenza H9N2 viruses induce nasal submucosal dendritic cells to sample luminal viruses via transepithelial dendrites and trigger subsequent DC maturation.
    Qin T; Yin Y; Wang X; Liu H; Lin J; Yu Q; Yang Q
    Vaccine; 2015 Mar; 33(11):1382-92. PubMed ID: 25613720
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Riboflavin as a Mucosal Adjuvant for Nasal Influenza Vaccine.
    Yin Y; Wang J; Xu X; Zhou B; Chen S; Qin T; Peng D
    Vaccines (Basel); 2021 Nov; 9(11):. PubMed ID: 34835227
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Heterosubtypic cross-protection induced by whole inactivated influenza virus vaccine in mice: influence of the route of vaccine administration.
    Budimir N; de Haan A; Meijerhof T; Gostick E; Price DA; Huckriede A; Wilschut J
    Influenza Other Respir Viruses; 2013 Nov; 7(6):1202-9. PubMed ID: 24102979
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Long-Lasting Mucosal and Systemic Immunity against Influenza A Virus Is Significantly Prolonged and Protective by Nasal Whole Influenza Immunization with Mucosal Adjuvant N3 and DNA-Plasmid Expressing Flagellin in Aging In- and Outbred Mice.
    Hinkula J; Nyström S; Devito C; Bråve A; Applequist SE
    Vaccines (Basel); 2019 Jul; 7(3):. PubMed ID: 31315253
    [No Abstract]   [Full Text] [Related]  

  • 7. CpG DNA assists the whole inactivated H9N2 influenza virus in crossing the intestinal epithelial barriers via transepithelial uptake of dendritic cell dendrites.
    Yin Y; Qin T; Wang X; Lin J; Yu Q; Yang Q
    Mucosal Immunol; 2015 Jul; 8(4):799-814. PubMed ID: 25492476
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Advax augments B and T cell responses upon influenza vaccination via the respiratory tract and enables complete protection of mice against lethal influenza virus challenge.
    Tomar J; Patil HP; Bracho G; Tonnis WF; Frijlink HW; Petrovsky N; Vanbever R; Huckriede A; Hinrichs WLJ
    J Control Release; 2018 Oct; 288():199-211. PubMed ID: 30218687
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Induction of heterosubtypic cross-protection against influenza by a whole inactivated virus vaccine: the role of viral membrane fusion activity.
    Budimir N; Huckriede A; Meijerhof T; Boon L; Gostick E; Price DA; Wilschut J; de Haan A
    PLoS One; 2012; 7(1):e30898. PubMed ID: 22303469
    [TBL] [Abstract][Full Text] [Related]  

  • 10. An alphavirus-based adjuvant enhances serum and mucosal antibodies, T cells, and protective immunity to influenza virus in neonatal mice.
    Khalil SM; Tonkin DR; Snead AT; Parks GD; Johnston RE; White LJ
    J Virol; 2014 Aug; 88(16):9182-96. PubMed ID: 24899195
    [TBL] [Abstract][Full Text] [Related]  

  • 11. H9N2 influenza whole inactivated virus combined with polyethyleneimine strongly enhances mucosal and systemic immunity after intranasal immunization in mice.
    Qin T; Yin Y; Huang L; Yu Q; Yang Q
    Clin Vaccine Immunol; 2015 Apr; 22(4):421-9. PubMed ID: 25673304
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Heterologous prime-boost H1N1 vaccination exacerbates disease following challenge with a mismatched H1N2 influenza virus in the swine model.
    Pliasas VC; Neasham PJ; Naskou MC; Neto R; Strate PG; North JF; Pedroza S; Chastain SD; Padykula I; Tompkins SM; Kyriakis CS
    Front Immunol; 2023; 14():1253626. PubMed ID: 37928521
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Critical role of TLR7 signaling in the priming of cross-protective cytotoxic T lymphocyte responses by a whole inactivated influenza virus vaccine.
    Budimir N; de Haan A; Meijerhof T; Waijer S; Boon L; Gostick E; Price DA; Wilschut J; Huckriede A
    PLoS One; 2013; 8(5):e63163. PubMed ID: 23658804
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Examination of the effects of virus inactivation methods on the induction of antibody- and cell-mediated immune responses against whole inactivated H9N2 avian influenza virus vaccines in chickens.
    Astill J; Alkie T; Yitbarek A; Taha-Abdelaziz K; Bavananthasivam J; Nagy É; Petrik JJ; Sharif S
    Vaccine; 2018 Jun; 36(27):3908-3916. PubMed ID: 29853199
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Enhanced pulmonary immunization with aerosolized inactivated influenza vaccine containing delta inulin adjuvant.
    Murugappan S; Frijlink HW; Petrovsky N; Hinrichs WL
    Eur J Pharm Sci; 2015 Jan; 66():118-22. PubMed ID: 25459531
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Intranasal administration of a flagellin-adjuvanted inactivated influenza vaccine enhances mucosal immune responses to protect mice against lethal infection.
    Hong SH; Byun YH; Nguyen CT; Kim SY; Seong BL; Park S; Woo GJ; Yoon Y; Koh JT; Fujihashi K; Rhee JH; Lee SE
    Vaccine; 2012 Jan; 30(2):466-74. PubMed ID: 22051136
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Exploring Prime-Boost Vaccination Regimens with Different H1N1 Swine Influenza A Virus Strains and Vaccine Platforms.
    Parys A; Vandoorn E; Chiers K; Passvogel K; Fuchs W; Mettenleiter TC; Van Reeth K
    Vaccines (Basel); 2022 Oct; 10(11):. PubMed ID: 36366335
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Intranasal vaccination with replication-defective adenovirus type 5 encoding influenza virus hemagglutinin elicits protective immunity to homologous challenge and partial protection to heterologous challenge in pigs.
    Braucher DR; Henningson JN; Loving CL; Vincent AL; Kim E; Steitz J; Gambotto AA; Kehrli ME
    Clin Vaccine Immunol; 2012 Nov; 19(11):1722-9. PubMed ID: 22933397
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Mucosal Immunity and Protective Efficacy of Intranasal Inactivated Influenza Vaccine Is Improved by Chitosan Nanoparticle Delivery in Pigs.
    Dhakal S; Renu S; Ghimire S; Shaan Lakshmanappa Y; Hogshead BT; Feliciano-Ruiz N; Lu F; HogenEsch H; Krakowka S; Lee CW; Renukaradhya GJ
    Front Immunol; 2018; 9():934. PubMed ID: 29770135
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Role of trimethylated chitosan (TMC) in nasal residence time, local distribution and toxicity of an intranasal influenza vaccine.
    Hagenaars N; Mania M; de Jong P; Que I; Nieuwland R; Slütter B; Glansbeek H; Heldens J; van den Bosch H; Löwik C; Kaijzel E; Mastrobattista E; Jiskoot W
    J Control Release; 2010 May; 144(1):17-24. PubMed ID: 20100528
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.